Last edition
News about "Gilead"
Gilead Sciences Wins FDA Accelerated Approval for First HDV Treatment Hepcludex
Gilead Sciences receives Food and Drug Administration (FDA) accelerated approval for Hepcludex, the first and only approved treatment for chronic Hepatitis Delta Virus (HDV), addressing a major unmet need in severe viral hepatitis care.
Gilead | 26/05/2026 | By News Bureau
South Africa pushes for local manufacturing of Gilead's HIV prevention drug
Gilead Sciences’ long-acting HIV prevention drug, lenacapavir, could soon be produced in South Africa as the government pushes to expand regional manufacturing and improve access to the therapy.
Gilead | 05/03/2026 | By Darshana | 125
Lupin Receives Tentative Approval from US FDA for its HIV treatment tablets
Lupin has received tentative US FDA approval for Bictegravir, Emtricitabine and Tenofovir Alafenamide Tablets to treat HIV, bioequivalent to Gilead’s Biktarvy, for adults and paediatric patients over 25 kg.
Gilead | 25/09/2025 | By Dineshwori | 210
Gilead breaks ground on new manufacturing hub as part of USD 32 billion US investment plan
Gilead Sciences has begun construction of a new Pharmaceutical Development and Manufacturing hub at its headquarters in Foster City, California, as part of a USD 32 billion investment programme to expand its manufacturing capabilities in the United States.
Gilead | 05/09/2025 | By Darshana | 327
Cognizant Extends Alliance with Gilead to Boost Advanced Technology Applications
Gilead is expected to enhance its efficiency through leveraging Cognizant's expertise in AI and advanced technology applications.
Gilead | 03/02/2025 | By Aishwarya | 418
Positive nod from FDA for Gilead's Maryland site
Gilead targets 400 jobs, assembles cell therapy manufacturing troika with FDA nod for Maryland site.
Gilead | 23/04/2022 | By Sudeep Soparkar | 1038
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy